- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07640321
Oral Sialic Acid Product Beauty Efficacy Test
June 8, 2026 updated by: Wuhan CASOV Green Biotech Co., Ltd
Assessment and Comparison on 3 Groups of 25 Human Beings of the Effect on the Cutaneous State, the Dermis Echogenicity, the Moisturizing Effect, the Depigmenting Effect, the Effect on the Biomechanical Properties and the Effect on Wrinkles, Color and Homogeneity and Pigmentary Spots of Cosmetic Product N°1 vs Cosmetic Product N°2 vs Placebo After Oral Intake in Conditions of Normal Use During 28, 56 and 84 Days: Self-assessment of the Cosmetic Qualities and Efficacy
Evaluate and compare the effects on female facial skin of oral placebo (Product A), N-acetylneuraminic acid (Product B), and ACAI-PLUS (Product C) after 28, 56, and 84 days under normal usage conditions.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
83
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430071
- COSderma China Laboratory (Wuhan, China)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
Chinese Asian women aged 40-65, with facial skin issues such as pigmentation spots, lack of elasticity, and wrinkles
Description
Inclusion Criteria:
- Skin type origin: Asian in China
- Age: from 40 to 65 years old
- Gender: female
Specific criteria:
• All skin type on the face Dry, dry combination, normal
presenting with a lack of elasticity to the face, inclusion grade
≤ 6 according 10 points scale
- presenting with a lack of density to the face, inclusion grade ≤ 6 according 10 points scale
- presenting with wrinkles on crow's feet area, grade ≥ 2 according to Skin ageing atlas Vol.2 (p.41)
- presenting with pigmentary spots with at least one with diameter ≥ 3mm
- Usual or occasional user of food supplements
- Able to give her informed consent
Exclusion Criteria:
The non-inclusion general criteria were the following ones:
- allergies or reactivity to cosmetic products,
- for the subjects undergoing hormonal treatment; change of treatment within 3 months preceding the inclusion visit,
- expectation of change in the current hormonal treatment during the study,
- anti-allergic, antibiotic, anti-inflammatory, dermatological treatment or corticosteroid therapy within 2 weeks before the inclusion visit,
- having a chronic pathology,
- performing or prevision to perform another test during the study or during the exclusion period,
- employee of the COSderma laboratory,
- pregnant or breast-feeding woman,
- woman not taking precaution to prevent pregnancy.
The non-inclusion specific criteria were the following ones:
- application of care products to the face within 48 hours preceding the inclusion visit,
- application of make-up products to the face the day of the inclusion visit,
- face wash with any other means than clear water (no soap or cleanser) on the day of the inclusion visit,
- application of self-tanning products to the face within 4 weeks preceding the inclusion visit,
- Oral intake of food supplement within 1 month preceding the inclusion visit,
- cutaneous marks on the face which could interfere with the skin's clinical signs assessment (pigmentation issues, scar tissues, over-developed hairiness, too many ephelides and naevi, sunburns...),
- solar exposition (natural sun or UVA or heliotherapy treatment) within 4 weeks preceding the inclusion visit and expectation of solar exposition (natural or UVA) during the study,
- Vitamin A acid treatment or its derivatives within 3 months preceding the pre-inclusion visit,
- Retinoid based oral treatment within 6 months before the pre-inclusion visit, or local treatment within 2 months prior to this visit,
- Carotene based treatment within 4 weeks preceding the inclusion visit,
- expectation or having undergone aesthetic or dermatological surgery on the face.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Group A
placebo
|
Oral placebo once daily for 84 consecutive days
|
|
Group B
N-acetylneuraminic acid
|
Oral N-acetylneuraminic acid, once daily, for 84 consecutive days
|
|
Group C
ACAI-PLUS
|
Oral ACAI-PLUS, once a day, for 84 consecutive days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Skin clinical scores
Time Frame: Day0、Day28、Day56、Day84
|
Dermatologists use a 10-point scale (0-9) and Volume 2 of the Atlas of Skin Aging for visual/tactile assessment.
(includes elasticity, firmness, crow's feet, under-eye wrinkles, facial sagging, skin tone radiance, moisturization)
|
Day0、Day28、Day56、Day84
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-assessment by subjects
Time Frame: Day0、Day28、Day56、Day84
|
Subjects self-rated using a 10-point scale (0-9).
(includes skin beauty, visibility of wrinkles, skin tone evenness, radiance, firmness)
|
Day0、Day28、Day56、Day84
|
|
Dermal echo parameters
Time Frame: Day0、Day28、Day56、Day84
|
Using Dermcup® high-frequency B-mode ultrasound scanning (25 MHz probe) to obtain dermal echo parameters
|
Day0、Day28、Day56、Day84
|
|
Color and clarity of spots
Time Frame: Day0、Day28、Day56、Day84
|
Dermatologists use Pantone color cards to score the color and clarity of spots
|
Day0、Day28、Day56、Day84
|
|
Wrinkles, skin tone uniformity, and spots
Time Frame: Day0、Day28、Day56、Day84
|
COSderma Photobench photography + Newtone software analysis to obtain information on wrinkles, skin tone uniformity, and spots
|
Day0、Day28、Day56、Day84
|
|
Stratum corneum moisture index
Time Frame: Day0、Day28、Day56、Day84
|
Corneometer® CM825 capacitance measurement method to obtain Stratum corneum moisture index
|
Day0、Day28、Day56、Day84
|
|
Biomechanical properties of the skin
Time Frame: Day0、Day28、Day56、Day84
|
DTM310 Diastron® torque meter obtains information on skin biomechanical properties
|
Day0、Day28、Day56、Day84
|
|
Freckle removal effect
Time Frame: Day0、Day28、Day56、Day84
|
Siascope V® spectrophotometric intradermal analysis obtains information on freckle removal effects
|
Day0、Day28、Day56、Day84
|
|
Self-assessment of cosmetic quality and efficacy
Time Frame: Day28、Day56、Day84
|
By distributing 12 questionnaires to the subjects, self-assessment information on the quality and effectiveness of cosmetics was obtained.
A four-point Likert scale was used (Agree, Somewhat Agree, Somewhat Disagree, Disagree), and the questionnaire content included: 1. Skin feels better; 2. Skin becomes fairer; 3. Pigmentation on the skin lightens or decreases; 4. Skin becomes radiant; 5. Skin becomes more elastic; 6. Skin is firmer than before; 7. Skin wrinkles and fine lines improve; 8. Skin becomes moisturized/hydrated; 9. Skin's oil-water balance is better; 10.
Skin looks rejuvenated, full of energy; 11.
Sleep improves after consumption; 12. Memory improves after consumption.
|
Day28、Day56、Day84
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 25, 2023
Primary Completion (Actual)
December 22, 2023
Study Completion (Actual)
December 22, 2023
Study Registration Dates
First Submitted
June 2, 2026
First Submitted That Met QC Criteria
June 8, 2026
First Posted (Actual)
June 10, 2026
Study Record Updates
Last Update Posted (Actual)
June 10, 2026
Last Update Submitted That Met QC Criteria
June 8, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SECCR/2022-132-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Health Behavior
-
Holbaek SygehusCompletedHealth Behavior | Health Knowledge, Attitudes, Practice | Health-Related Behavior | Health LiteracyDenmark
-
University of PennsylvaniaNot yet recruiting
-
Yale UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedBehavior, HealthUnited States
-
Penn State UniversityCompletedBehavior, HealthUnited States
-
Henry Ford Health SystemUniversity of Kansas; University of Maryland, College ParkActive, not recruiting
-
University of PennsylvaniaNot yet recruitingBehavior, HealthUnited States
-
Istinye UniversityRecruitingHealth-Related BehaviorTurkey (Türkiye)
-
University of Texas Rio Grande ValleyHealth and Human Services Commission (HHSC); Pharr-San Juan-Alamo Independent... and other collaboratorsCompletedHealth-Related BehaviorUnited States
-
University of PrimorskaUniversity of Ljubljana, Faculty of Social Sciences; Ministry of Defence, SloveniaActive, not recruitingHealth-Related BehaviorSlovenia
-
University of LisbonRecruitingOral Health Behavior Change | Oral Health Care | Oral Health Self-efficacyPortugal
Clinical Trials on Oral placebo
-
Fulcrum TherapeuticsCompletedFacioscapulohumeral Muscular Dystrophy (FSHD)United States, Canada, France, Spain
-
Royan InstituteUnknownInfertilityIran, Islamic Republic of
-
Priovant Therapeutics, Inc.RecruitingCutaneous SarcoidosisUnited States
-
Pulmagen TherapeuticsCompleted
-
VA Office of Research and DevelopmentCompletedSuicidal IdeationUnited States
-
Eidos Therapeutics, a BridgeBio companyWithdrawnTransthyretin-Related (ATTR) Familial Amyloid PolyneuropathyUnited States
-
Evelo Biosciences, Inc.CompletedPsoriasis | Atopic DermatitisUnited Kingdom
-
Sao Thai Duong Joint Stock CompanyBig Leap Clinical Research Joint Stock CompanyCompleted
-
Basilea PharmaceuticaBiomedical Advanced Research and Development AuthorityCompleted
-
University of British ColumbiaCrohn's and Colitis CanadaWithdrawnInflammatory Bowel Diseases | Ulcerative ColitisCanada